Kalypsys, Inc.
Records under this name other than the patents Kalypsys, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,517,884 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR Term ended Term ended Sep 6, 2026 · From the USPTO record | Term ended | Term ended Sep 6, 2026 | From the USPTO record |
| US 7,834,004 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR Term ended Term ended Feb 14, 2026 · From the USPTO record | Term ended | Term ended Feb 14, 2026 | From the USPTO record |
| US 7,915,253 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR Term ended Term ended Feb 14, 2026 · From the USPTO record | Term ended | Term ended Feb 14, 2026 | From the USPTO record |
| US 7,494,999 | Sulfonyl-substituted bicyclic compounds as modulators of PPAR Term ended Term ended Jan 11, 2026 · From the USPTO record | Term ended | Term ended Jan 11, 2026 | From the USPTO record |
| US 9,463,189 | Sulfonyl-substituted bicyclic compounds as PPAR modulators for the treatment of non-alcoholic steatohepatitis Formerly held Lapsed on the fee record Ended Oct 11, 2024 · From the USPTO record | Lapsed on the fee record | Ended Oct 11, 2024 | From the USPTO record |
| US 8,859,550 | Heterocyclic inhibitors of histamine receptors for the treatment of disease Lapsed on the fee record Ended Oct 14, 2022 · From the USPTO record | Lapsed on the fee record | Ended Oct 14, 2022 | From the USPTO record |
| US 8,569,300 | Substituted tetrazolo[1,5-A]pyrazine inhibitors of histamine receptors for the treatment of disease Lapsed on the fee record Ended Oct 29, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 29, 2021 | From the USPTO record |
| US 9,078,887 | Bicyclic Heteroaryl Inhibitors of PDE4 Formerly held Lapsed on the fee record Ended Jul 14, 2019 · High confidence | Lapsed on the fee record | Ended Jul 14, 2019 | High confidence |
| US 8,258,154 | Bicyclic Heteroaryl Inhibitors of PDE4 Formerly held Lapsed on the fee record Ended Sep 4, 2016 · High confidence | Lapsed on the fee record | Ended Sep 4, 2016 | High confidence |
| US 8,138,205 | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 Lapsed on the fee record Ended Mar 20, 2016 · From the USPTO record | Lapsed on the fee record | Ended Mar 20, 2016 | From the USPTO record |